Kanglexin

Kanglexin is an orally active and novel anthraquinone compound. Kanglexin inhibits NLRP3 inflammatory body activation and cell pyroptosis, and has a cardioprotective effect. Kanglexin promotes angiogenesis through FGFR1/ERK signaling pathway and accelerates diabetic wound healing. In addition, Kanglexin has the effect of lipid-lowering and inhibiting the dedifferentiation of vascular smooth muscle cells, and can be used in the study of hyperlipidemia, fatty liver and atherosclerosis ^{[1] [2] [3] [4]}.

In Vivo, Kanglexin (20-40 mg/kg; oral gavage; 7 days) has an ameliorative effect in the myocardial infarction mouse model^[1]. Kanglexin (20-80 mg/kg; oral administration; 2 weeks) has an ameliorative effect in the hyperlipidemia rat model^[2].

In Vitro, Kanglexin (10-20 μM; 24 h) inhibits pyroptosis of cardiomyocytes treated with hypoxia or LPS ^[1]. Kanglexin (5-20 μM; 24 h) reduces lipid levels in Oleic acid treated HepG2 cells through AMPK/SREGBP-2/PCSK9/LDLR signaling pathway^[2].

References:
[1]. Bian Y, et al. Kanglexin, a novel anthraquinone compound, protects against myocardial ischemic injury in mice by suppressing NLRP3 and pyroptosis. Acta Pharmacol Sin. 2020 Mar;41(3):319-326.
[2]. Li X, et al. Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway. Biomed Pharmacother. 2021 Jan;133:110802.
[3]. Yang S, et al. Kanglexin counters vascular smooth muscle cell dedifferentiation and associated arteriosclerosis through inhibiting PDGFR. Phytomedicine. 2024 Jul 25;130:155704.
[4]. Zhao Y, et al. Kanglexin accelerates diabetic wound healing by promoting angiogenesis via FGFR1/ERK signaling. Biomed Pharmacother. 2020 Dec;132:110933.